Brief: FDA Approves Roche’S Tecentriq
09/10/2026 06:02
BRIEF-FDA Approves Roche’S Tecentriq Oct 9 (Reuters) - Roche Holding AG ROPC.S:
FDA APPROVES ROCHE’S TECENTRIQ IN COMBINATION WITH A FLUOROPYRIMIDINE AND OXALIPLATIN FOR THE ADJUVANT TREATMENT OF A CERTAIN TYPE OF STAGE III COLON CANCER
ROCHE HOLDING AG - TECENTRIQ PLUS CHEMOTHERAPY REDUCES RECURRENCE OR DEATH RISK BY 50% IN PHASE III ATOMIC STUDY
Source text: ID:nGNE7Y509M
Further company coverage: ROPC.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey